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Abstract  
The development of a diabetic cardiomyopathy is a multifactorial process, and evidence is 
accumulating that defects in intracellular free calcium concentration [Ca2+]i or its 
homeostasis are related to impaired mechanical performance of the diabetic heart leading 
to a reduction in contractile dysfunction. Defects in ryanodine receptor, reduced activity of 
the sarcoplasmic reticulum calcium pump (SERCA) and, along with reduced activity of the 
sodium-calcium exchanger (NCX) and alterations in myofilament, collectively cause a 
calcium imbalance within the diabetic cardiomyocytes. This in turn is characterized by 
cytosolic calcium overloading or elevated diastolic calcium leading to heart failure. 
Numerous studies have been performed to identify the cellular, subcellular and molecular 
derangements in diabetes-induced cardiomyopathy (DCM), but the precise mechanism(s) is 
still unknown. This review focuses on the mechanism behind DCM, the onset of contractile 
dysfunction and the associated changes with special emphasis on hyperglycaemia, 
mitochondrial dysfunction in the diabetic heart. Further, management strategies, including 
treatment and emerging therapeutic modalities are discussed.  
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Diabetes mellitus (DM) 
Diabetes mellitus (DM) is a heterogeneous metabolic disorder characterised by chronic 
hyperglycaemia (HG) that results in dysfunction in the cell’s ability to transport and utilize 
glucose [1]. Type 1 DM (T1DM), is caused by T lymphocyte-mediated autoimmune 
destruction of the pancreatic β-cells, resulting in insufficient insulin production and 
subsequent decrease in glucose utilization [2]. Type 2 DM (T2DM) results from an insulin 
resistance that instigates hypertrophy of the β-cell to compensate, and resulting in 
hyperinsulinemia leading to eventual insulin resistance [3, 4]. Advanced failure of the β-cells 
in T2DM decreases the amount of insulin produced resulting in pathophysiological changes 
that produce elevated blood glucose levels (hyperglycaemia), impaired cellular glycolysis 
and pyruvate oxidation [5]. In chronic hyperglycaemia, comorbidities include some long-
term complications as peripheral vascular disease, retinopathy, kidney failure, neuropathy 
and eventually, cardiac dysfunction/failure or cardiomyopathy [6].  
Currently, more than 422 million people worldwide – almost one in every 11, suffer from 
DM and this number is likely to increase to 650 million within the next 15-20 years [7], 
making it one of the five leading causes of death in developed and developing countries. 
Between 1980 and 2014 the number of adults with diabetes quadrupled from 108 million to 
422 million. The prevalence of DM was higher in the developed countries but now, the 
major increase in people with diabetes occurs in the developing countries such as China, 
India, and those in Middle East and Africa.  
Type 2 DM (T2DM) is specifically epidemic due to the rising rates of obesity throughout the 
world. Over one billion people worldwide are overweight (BMI >25 and <29.9) or obese 
(BMI >30) in most cases and they are also pre-diabetics [8]. With such high rates of 
morbidity and mortality, DM represents a major medical, sociological and economic 
challenge and burden to the national health services globally.  
Cardiovascular diseases (CVDs) are the leading cause of death throughout the world and on 
the basis of 2011 death rate data, mortality owing to cardiovascular disease accounted a 
astounding 2150 people dying daily with an average of 1 death every 40 seconds [9]. 
Interesting, CVD- related mortality with DM have been reported to be about 65% [10] and 
68% of adults with DM older than 65 years die of some form of heart disease.  The 
Framingham Heart Study demonstrated that the frequency of heart failure is five times 
greater in diabetic women and two times greater in diabetic men compared with age-
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matched control subjects [11,12].  
Diabetic heart disease is now recognized as an important and growing public health risk 
which affects the heart in three ways: cardiac autonomic neuropathy (CAN), coronary artery 
disease (CAD) due to accelerated atherosclerosis, and diabetic cardiomyopathy (DCM) [10].  
DCM is a heart failure syndrome found in diabetic patients that is characterized by impaired 
myocardial relaxation dynamics or diastolic dysfunction, and structural abnormalities 
leading to left ventricular hypertrophy (LVH) or a combination of these [13]. Presently, DCM 
is defined as myocardial dysfunction (MD) in patients with DM in the absence of 
hypertension and structural heart diseases such as valvular heart disease or CAD [14]. 
Other features of DCM include: interstitial fibrosis, myocyte hypertrophy [15], lipid 
accumulation in cardiomyocytes and fetal gene reactivation [16]. Furthermore, DCM is also 
accompanied by comorbidities such as obesity, smoking, hypertension and others and these 
complications often precede the development of systolic dysfunction, CAD and heart failure 
[17].  
With DM being a well-known risk factor for the development of heart failure, which leads to 
a poor quality of life in affected individuals, the situation now becomes complicated in 
treatment of DM resulting in alteration of the pharmacokinetics of anti-diabetic 
medications. Therefore, in this review we focus on the mechanism behind DCM, the onset 
of contractile dysfunction and the associated changes with special emphasis on 
hyperglycaemia, mitochondrial dysfunction in the diabetic heart and management 
strategies, including treatment and emerging therapeutic directions.  
 
Mechanism of DCM  
 
Several factors are involved in the development of diabetic cardiomyopathy, including 
metabolic, biochemical, and ultrastructural changes within the cardiac myocyte [18,19]. In 
particular, because of the primary role of mitochondria in ATP production, weakening of 
mitochondrial respiratory function is a key contributing factor to decreased contractile 
function of the diabetic heart. Numerous mechanisms have been proposed to contribute to 
this clinical situation, including oxidative stress, microvascular abnormalities, and decreased 
sarcoplasmic reticular calcium uptake [20]. Other proposed mechanisms include: subcellular 
component abnormalities, metabolic disturbances, cardiac autonomic dysfunction, 
alterations in the renin-angiotensin-aldosterone system (RAAS), and maladaptive immune 
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responses [21]. However, the molecular mechanisms that cause this cardiac dysfunction are 
still largely undefined. An established hypothesis is that hyperglycemia plays a critical role in 
the development of DCM, though multiple complex mechanisms and the interplay of many 
metabolic and molecular events within the myocardium and plasma contribute to its 
pathogenesis. The principal metabolic abnormalities in DM are hyperglycemia and 
hyperlipidemia, all of which stimulate the production of reactive oxygen species (ROS) or the 
nitrogen species that cause most diabetic complications, including DCM and diabetic 
nephropathy [22]. These abnormalities further induce alterations in downstream 
transcription factors, which result in changes in gene expression, myocardial substrate 
utilization, myocyte growth, endothelial function and myocardial compliance. 
 
The development of DCM is a multifactorial process, and accumulating evidence has 
revealed that defects in [Ca2+]i homeostasis are related to impaired mechanical performance 
of the diabetic heart leading to the prevalence of contractile dysfunction [23]. It has been 
suggested that diastolic dysfunction may be due to cardiomyocyte hypertrophy and 
myocardial fibrosis. In turn, at cellular level, these are associated with defects in calcium 
transport and mitochondrial calcium uptake due to mitochondrial dysfunction and reduced 
activity of SERCA pump which are all responsible for calcium sequestration during 
cardiomyocyte diastolic relaxation [24-26]. Also, there is much evidence that reduced 
activity of NCX, myocardial contractile protein collagen formation and fatty acid metabolism 
are also associated with diastolic dysfunction. In vivo functional changes include decreased 
ventricular filling, decreased ventricular ejection fraction, decreased fractional shortening, 
increased ventricular wall stiffness and increased pre-ejection time [17]. 
As stated in the aforementioned section, hyperglycaemia stimulates an increase in reactive 
oxygen species (ROS) and reactive carbonyl species (RCS) production, because of increased 
input of reducing equivalents into the mitochondrial electron transport chain [27-28]. 
Hyperglycaemia-induced cell damage is a consequence of increased flux through metabolic 
pathways (polyol pathway flux, advanced glycation- end product formation, activation of 
protein kinase C (PKC) isoforms and increased hexosamine pathway flux) [22,29]. 
Mitochondrial function is highly impaired by hyperglycaemic conditions in part because of 
decreased mitochondrial transcription factor A (TFAM) activity and/or expression [30-31].  
These topics will be discussed more in-depth in subsequent sections. 
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Glucose metabolism regulation by insulin and fatty acids 
It was reported over 40 years ago [32] that glycolytic metabolism is increased in cardiac 
hypertrophy and congestive hearth failure and it is now well-known that cardiac glucose 
metabolism declines in diabetes [33] due to a decline in insulin, insulin resistance or 
increased availability of fatty acids. Healthy hearts derive most of their energy from free 
fatty acids and only a small proportion from circulating glucose while; in contrast, diabetic 
hearts use more fat and less glucose than normal hearts. 
The diabetic heart is characterized by distinctive metabolic events including elevations in 
fatty acid uptake and oxidation combined with a decrease in glucose uptake and oxidation. 
A major factor in the elevated uptake and oxidation of fatty acids in cardiomyocytes has 
been linked to Increased release of fatty acids by the adipocyte and liver resulting in 
elevated circulating fatty acids and triglycerides. [34]. In the heart, utilization of glucose 
stimulated by insulin, is inhibited by fatty acid metabolism via transcriptional regulation of 
limiting enzymes. The generation of enzymes of fatty acid oxidation entails the 
transcriptional regulators PPARα and/or PPARβ, which regulate gene expression of these 
enzymes and are elevated and activated in diabetic hearts [25]. It has been suggested that 
the presence of glucose reduces fatty acid metabolism, probably by increasing intracellular 
levels of malonyl CoA [36], while increased fat dependence also appears to play a role in the 
function of decreased glucose metabolism. The initial step in cardiomyocyte glucose usage is 
uptake, which is significantly regulated by insulin in the heart. In DM there is also a 
persistent reduction in cardiac glycolytic capacity [37] and glucose oxidation is further 
reduced by a decline in pyruvate dehydrogenase activity [37,38]. 
The concept of limiting enzymes and limiting steps in glucose metabolism has been reported 
to contribute to development of DCM [27] where limiting steps have become potential sites 
of pathology.  The concept of one such limiting step was explained by Randle et al. [32] in 
the 1960’s and more recently by An and Rodrigues [5] relating to glucose uptake via the 
glucose transporters GLUT1 and GLUT4 in myocardial glucose metabolism. These authors 
underlined that enabling of glucose transport by insulin involves both the translocation of 
GLUT4 to the cell membrane and the upregulation of the transporter, an effect that is 
impaired in diabetes. It was reported that despite the significant reduction in glucose 
uptake, the size of the intracellular glucose pool is elevated in the type 1 diabetic heart. 
7 
 
[31]. Data collected revealed that impaired GLUT4 activity in the diabetic heart does not 
limit glycolytic flux and would imply that key bottlenecks in glycolysis develop downstream 
from the glucose transporters in the diabetic heart. 
Glycolysis is the metabolic pathway that involves a sequence of ten enzyme-catalysed 
reactions, which converts glucose into pyruvate. One such important limiting enzyme in the 
diabetic heart is phosphofructokinase (PFK), which catalyses the conversion of fructose-6-
phosphate to fructose 1,6 bisphosphate. Enhanced rates of fatty acid β -oxidation lead to 
elevations in cardiac levels of both acetyl CoA and citrate, and it has been shown previously 
that citrate is a potent inhibitor of PFK [40]. Thus, this enzyme is a key target of fatty acid-
mediated regulation of glycolysis. Owing to the fact that diabetes is associated with 
enhanced rates of fatty acid β - oxidation and elevations in citrate levels, it has been 
proposed that PFK activity is diminished in the diabetic heart [40]. Further research also 
implicates this enzyme as a major sensor of the high-energy phosphate content of the heart 
[41]. Elevations in AMP kinase activity as well as low ATP/ADP ratio has shown to stimulate 
the activity of this allosteric enzyme. 
Other researchers [42] have proposed data supporting a role for PFK in diabetes-mediated 
glycolytic impairment that correlate with elevations in glucose-6-phosphate levels and 
reductions in fructose 1,6 bisphosphate content. Based upon these findings, a bottleneck 
consequently develops in the glycolytic pathway of the diabetic heart, resulting in an 
increase in myocardial levels of glucose-6-phosphate and fructose-6- phosphate. These 
events have important pathological consequences, as they serve as substrates for four 
pathological pathways involved in the development of DCM (see Figure 1). 
Other limiting steps/enzymes in regulation of glucose metabolism in the heart include: (I) 
the three- enzyme pyruvate dehydrogenase complex (PDH) and (II) Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) – especially during myocardial ischemia. 
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Figure 1: Flow diagram showing metabolic mechanisms of diabetic cardiomyopathy and how 
ROS from the mitochondria can leave the mitochondria as H2O2 and activate PKC in the 
cytosol. PFK- phosphofructokinase; DAG – diacylglycerol; PKC – protein kinase C; FA – fatty 
acid; NADH – nicotinamide adenine dinucleotide (reduced form); FADH – flavin adenine 
dinucleotide (reduced form); diagram drawn by hand. 
 
Mitochondrial dysfunction and changes in PKC activities in the diabetic heart 
Mitochondrial acetyl Co-A is a crucial factor of the citric acid cycle. In mammalian cells, 
mitochondrial acetyl-CoA is produced from pyruvate or by the β-oxidation of fatty acids, and 
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then feeds into the citric acid cycle. Since the 1960’s researchers [43] have highlighted the 
important role of acetyl-CoA in diabetic heart. Bowman [43] concluded that elevated levels 
of citric acid cycle intermediates in hearts of diabetic rats and in normal hearts perfused 
with fatty acids and ketone bodies are due largely to increased availability of acetyl-CoA. 
Another factor that plays an important determinant role in the citric acid cycle flux is 
slowing of the respiratory chain flux. Several authors have suggested [44-47] that this event 
would contribute to the inhibition of α -ketoglutarate dehydrogenase and elevate the 
NADH/NAD+ ratio, which in turn, would result in diminished citric acid flux. 
Complexes in the respiratory chain are determined by the transcriptional activity of 
mitochondrial transcription factor A (TFAM), which is essential for mitochondrial DNA 
transcription and replication. It has been proposed [48] that TFAM transcriptional activity is 
decreased in diabetic cardiomyopathy and TFAM activity may be responsible for some of 
the alterations caused by hyperglycaemia. These researchers [48] investigated the effect of 
TFAM overexpression on hyperglycaemia-induced cytosolic calcium handling and 
mitochondrial abnormalities. They discovered that overexpression of TFAM dramatically 
affects the function of neonatal rat cardiomyocytes incubated in medium containing 30 mM 
glucose. ATP content was reduced by 30% and mitochondrial calcium decreased by 40% 
after high glucose. Calcium transients were prolonged by 70% after high glucose, which was 
associated with diminished sarco(endo)plasmic reticulum Ca2+-ATPase 2a and cytochrome-c 
oxidase subunit 1 expression. In summary, it was demonstrated that: (I) hyperglycaemia 
increases the levels of O-GlcNAcylated TFAM, which diminishes the activity of TFAM and 
reduces the activity of oxidative phosphorylation and (II) TFAM overexpression protected 
cell function against the damage induced by high glucose in cardiomyocytes. 
An additional consequence of weakened respiratory chain flux is the generation of reactive 
oxygen species (ROS) – produced as electrons are diverted from the respiratory chain to the 
acceptor oxygen.  
Figure 1 shows how ROS (O2-) generated from the mitochondria can leave the organelles as 
H2O2 and activate PKC in the cytosol. The outcome of PKC activation by ROS, in turn, triggers 
activation of NADPH oxidase and results in considerably increased cytosolic ROS content. 
Consequently, diabetes-mediated mitochondrial dysfunction contributes to the 
development of DCM by altering ATP generation and Ca2+ movement. 
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Protein kinase C (PKC) has been shown to inhibit sarcoplasmic reticular Ca2+ pump and 
myofibrillar ATPase [49,50] activities, and several investigators have suggested that 
subcellular changes in the diabetic heart may be due to alterations in the PKC activity and/or 
PKC-mediated signal transduction mechanism. Some examples include (I) increased 
phosphorylation of troponin-I in the diabetic heart has been considered to be due to the 
activation of PKC [51,52] and (II) diabetes is related with translocation of the -isoform of 
PKC from cytosolic to particulate fraction of cardiomyocytes. This change is prevented by 
the blockade of angiotensin II receptors, which are known to activate PKC [51] and it has 
also been established that concentration of diacylglycerol, a known activator of PKC [53] 
was increased in the diabetic heart. 
One important study undertaken by Liu et al. [54] examined PKC activities in the 
homogenate, cytosolic, and particulate fractions from diabetic hearts. They found Ca2+-
dependent PKC activity was increased by 43 and 51% in the homogenate fraction and 31% 
and 70% in the cytosolic fraction from the 4- and 8-weeks diabetic hearts while Ca2+-
independent PKC activity was increased by 24% and 32% in the homogenate fraction and 
52% and 89% in the cytosolic fraction respectively, both cases in comparison with control 
values. They also examined changes in the contents of different PKC isozymes in cardiac 
homogenate, cytosolic, and particulate fractions in diabetes induced by streptozotocin (STZ) 
in rats.  The results showed relative protein contents of PKC--- and , isozymes were 
increased by 43%, 31%, 48%, and 38%, respectively, in the homogenate fraction and by 
126%, 119%, 148%, and 129%, respectively, in the cytosolic fraction of the 8-weeks diabetic 
heart. These results provided reliable evidence that the increased myocardial PKC activity 
and increased protein contents of the cytosolic PKC isozymes are associated with subcellular 
alterations and cardiac dysfunction in the diabetic heart. 
For more in-depth review and explanations on regulation of myocardial glucose, fatty acid 
metabolism diseases and dysfunctions, several excellent review articles have been 
published in the area of diabetes induced cardiac dysfunction [55-59]. 
 
Role of HG and its biochemical pathways in the development of cardiac 
dysfunction  
Various mechanisms of HG are responsible for the generation of diabetes-induced heart 
disease, including metabolic abnormalities such as cellular calcium overload and altered 
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calcium metabolism in cardiomyocytes leading to contractile dysfunction [60-63]. One major 
contributor to HG-induced diabetic abnormalities is increased oxidative stress along with 
depleted antioxidant defences and raised levels of reactive oxygen species (ROS). Persistent 
hyperglycaemia results in Increased glucose metabolism, which increases oxidative stress 
via the development of ROS from the mitochondria. ROS can cause damage to the 
mitochondria together with poly (ADP-ribose) polymerase-1 (PARP) activation leading to the 
inhibition of the cytosolic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
This inhibition initiates a series of cellular processes, by activating pathways that lead to HG-
associated cellular/tissue damage [64]. Inhibition of GAPDH diverts glucose from glycolytic 
pathways into alternative biochemical pathways, including advanced glycation end product 
(AGE) formation, hexosamine, polyol pathway, and protein kinase C (PKC) activation [65]. 
Increased formation of AGEs is involved in forming irreversible cross-links with 
macromolecules such as collagen leading to myocardial fibrosis, inactivation of SERCA2a and 
RyR2 calcium release channel, together with impaired cardiac contractility, relaxation and 
ventricular stiffness [66-69]. Increased polyol flux is associated with reduced levels of 
intracellular glutathione and an increase in cardiac cell apoptosis [70]. Furthermore, 
inhibition of this pathway has been claimed to provide protection for the heart from 
ischaemic injury [71]. The hexosamine biosynthetic pathway is known for reducing SERCA2a 
mRNA and protein expression, along with reduced SERCA2a promoter activity via increased 
nuclear O-GlcNAcylation. This results in prolonged calcium transients and impaired 
myocardial relaxation [72-73]. Finally, the activation of protein kinase C (PKC) via de novo 
synthesis of the lipid second messenger diacylglycerol (DAG) leads to vascular alterations at 
pathological, cellular and functional levels which include basement membrane thickening, 
extracellular matrix expansion, vascular permeability, enzymatic alterations such as Na+- K+- 
ATPase, and MAP kinase, multifocal fibrosis, myocyte necrosis, decreased left ventricular 
performance and left ventricular hypertrophy [74]. Impaired calcium handling and cellular 
efflux may further contribute to impaired relaxation, or diastolic dysfunction. Overall, HG via 
multiple biochemical pathways results in myocardial, cellular and functional changes, all 
which contribute to the development of a cardiomyopathy leading to HF. Figure 2 illustrates 
these pathways as a flow chart. 
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Figure 2: A schematic flow chart representation highlighting the role of hyperglycaemia and 
its biochemical pathways including hexosamine biosynthetic pathway, Protein Kinase C 
(PKC) pathway, advanced glycation end-products pathway and the Polyol flux pathway in 
the development of cardiac dysfunction. {DAG; diacylglycerol, ECM; Extracellular Matrix, 
PARP; poly (ADP-ribose) polymerase-1, SERCA; sarcoplasmic reticulum Ca2+-ATPase}. See 
text for discussion; Diagram drawn by hand. 
 
Regulation of calcium in normal cardiac muscle 
The major function of the heart is to pump blood efficiently by virtue of an orchestrated 
contraction–relaxation cycle of the working cardiomyocytes. Contractility of these 
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cardiomyocytes is regulated by a spatially defined programme of ion channels and 
exchangers that precisely control Ca2+ entry in and out of the cell and the SR. Regulation of 
contractility and hence, the control of Ca2+ release is principally achieved via the electrical 
activity of the sarcolemma. Depolarization of the cardiac cell membrane, during a normal 
action potential is sustained in the plateau phase by the activation of voltage-gated L-type 
Ca2+ channels (ICa,L) [75]. It is this small influx of Ca2+ via these channels that triggers a 
much larger release of Ca2+ from the SR by a process called calcium–induces calcium release 
(CICR). Upon activation of the SR, there is a transient rise in cytoplasmic Ca2+ concentration 
[Ca2+]i. This phenomena is commonly referred to as the calcium transient [Ca2+]i and this 
CICR process is generally accepted as the major mechanism of Ca2+ release from the SR. Ca2+ 
release from the SR is mediated by intracellular calcium receptors commonly known as 
ryanodine receptors (RyR), with type 2 RyRs being the most abundant intracellular Ca2+ 
channels in cardiomyocytes [75,76]. Contraction is initiated when free Ca2+ causes the 
interaction of the myofilaments via troponin C and the thick and thin filaments, namely 
actin and myosin leading to cell shortening. Exclusion of Ca2+ from the cytosol is achieved 
mainly by several mechanisms, including SR uptake via the SR Ca2+ transporter (SERCA), 
removal through the sarcolemma via the NCX and to a small extent by the Ca2+-ATPase 
pump [77-78]. These changes result in both cyclic increases and decreases in Ca2+ and in 
contractility of the individual myocytes. 
In diabetic cardiomyopathy, it is well known that Ca2+ homeostasis is deranged leading to 
elevated diastolic Ca2+. This is due to a failure of SERCA to pump back Ca2+ into the SR, 
increased asyncrynous SR Ca2+ leak via RyRs and dysfunction of the NCX. These three Ca2+ 
transport proteins participate during calcium transient [Ca2+]i decline leading to a slow 
steady-state in resting Ca2+ [77]. In the new balanced state, a generously proportioned 
fraction of activating Ca2+ also enters the cell at each beat via the L-type Ca2+ channel (e.g. 
smaller Ca2+ release causes less Ca2+ inactivation). Consequently, these 4 major transporting 
proteins have been identified and they seem to contribute to the disturbed diastolic Ca2+ 
accumulation observed in the failing heart. Firstly, increased Ca2+ leak through RyR, secondly 
reduced SERCA activity, decreased trans-sarcolemal elimination of Ca2+ by the NCX and lastly 
the L-type Ca2+ channel [79-80]. These issues are further examined in the following text.  
Ryanodine receptor dysfunction  
A major feature in diabetic cardiomyopathy is the increased Ca2+ leak from the SR due to 
enhanced RyR open probability. Because leak, as measured by Ca2+ sparks, is increased with 
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higher SR Ca2+ load, any intervention to increase SR Ca2+ load without reducing the leak 
decreases efficiency of ECC process with increased energy consumption with arrhythmias as 
potential side effects [79,81]. 
RyRs were first observed in the 1970’s as ‘foot’ structures in electron micrograph images of 
striated muscle filling the gaps that are found at specific junctions between the sarcolemma 
and the SR membrane [82-83]. Lai and colleagues identified the RyR as an integral SR 
membrane protein with a role in Ca2+ release [84]. The complementary DNA encoding three 
distinct RyR channels was cloned and the corresponding gene sequences obtained for three 
isoforms; RyR1 [85-86], RyR2 [87-88], and RyR3 [89]. It was not until the 1990s that the 
central role of RyRs through numerous biochemical, physiological, molecular and 
pharmacological studies and the physiological characteristics of excitation–contraction 
coupling (ECC) were recognized [89-91]. During the past decade numerous discoveries have 
been made of RyR2 gene mutations, which underlie the arrhythmogenesis leading to 
sudden cardiac death, which has added a new focus to the role of RyR2 dysfunction in 
cardiac disease [79-80, 92-93]. 
 
Dysregulation of sarcoplasmic reticulum and Na+/H+, Na+/K+ & Na+/Ca2+ 
exchange 
The sarcoplasmic reticulum (SR) constitutes the main intracellular calcium store in striated 
muscle and it plays an important physiological role in the regulation of excitation-
contraction-coupling (ECC) and of intracellular calcium concentrations during contraction 
and relaxation. Intracellular pH and [Na+] in the heart are regulated by the sarcolemmal 
membrane Na+/H+ exchange pathway. DCM is characterized by reduced cardiac contractility 
due to direct changes in myocardium function independent of vascular disease. It is now 
becoming clear that cardiac dysfunction in chronic diabetes is I ntimately involved with Ca2+-
handling abnormalities in the diabetic heart. These abnormalities occur mainly due to 
defects in sarcolemmal Na+/K+ ATPase, Na+/Ca2+ exchange, Na+/H+ exchange, Ca2+-channels 
and Ca2+-pump activities as well as changes in sarcoplasmic reticular Ca2+-uptake and Ca2+-
release processes; these alterations may lead to the occurrence of intracellular Ca2+ 
overload.  
This section investigates the alterations of cardiac sarcoplasmic reticulum Ca2+-ATPase 
activity and cardiac function. 
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Early innovative work performed by Ganguly et al. [94] investigated the defective 
sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. The results of this 
study provided some evidence that the depression in cardiac sarcoplasmic reticular calcium 
accumulation during diabetes is a consequence of insulin deficiency and associated chronic 
metabolic changes, but the hypothyroid condition that accompanies experimental diabetes 
does not appear to play any role in this defect. In follow-up research [95], experiments were 
designed to monitor rats that were injected with streptozotocin (65 mg/kg), killed 8–10 
weeks later, and sarcolemmal membrane vesicles isolated from pooled ventricles. The 
results from these studies showed significant depressions in Na+/K+-adenosine 
triphosphatase (ATPase) activity and Na+/Ca2+ exchanges were observed in the diabetic 
preparations in comparison to control. Further, a striking depression in cardiac sarcolemmal 
Na+/H+ exchange was observed in the diabetic animals in comparison to control.] Other 
studies, [96] focused on sarcolemmal Ca2+ transport in streptozotocin-induced diabetic 
cardiomyopathy in rats, provided results that indicated a depression in the ability of the cell 
to remove Ca2+ through Na+/Ca2+ exchange and Ca2+-pump mechanisms in sarcolemma. It 
was further concluded that these defects might contribute to the occurrence of intracellular 
Ca2+ overload and diabetic cardiomyopathy. Lun et al. [97] examined alterations in Ca2+-
channels during the development of diabetic cardiomyopathy with specific binding of 3H-
nitrendipine studied at different concentrations. The outcome of their studies showed 
significant decrease in both dissociation constant and maximal number of 3H-nitrendipine 
binding observed after 3 and 8 weeks. Also, it was revealed that treatment of diabetic 
animals with insulin prevented the occurrence of these changes in the myocardium. In 
summary, a relationship was seen between number of 3H-nitrendipine binding sites and 
increased affinity of Ca2+ channels with the former partly explaining the depressed cardiac 
contractile force development in chronic diabetes, and latter, partly explaining the 
increased sensitivity of diabetic heart to Ca2+. 
Further work by Dhalla et al. [98] highlighted the fact that while reductions in sarcoplasmic 
reticular Ca2+ pump and Ca2+ release channel function are associated with cardiac 
dysfunction, alterations in sarcolemmal Na+/Ca2+ exchanger and Na+/K+ ATPase activities 
contribute to intracellular Ca2+ overload at late stages of diabetes. The constant buildup of 
Ca2+ in mitochondria produces Ca2+ overload in these organelles, and this change induces 
impairment of energy production, depletion of energy stores, as well as further promotion 
of oxidative stress in chronic diabetes. These observations, coupled with generation of 
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oxyradicals results in the opening of mitochondrial pores, leakage of toxic proteins and 
myocardial cell damage in diabetes, supports the view that alterations in sarcoplasmic 
reticular and mitochondrial functions produce intracellular Ca2+ overload and therefore, play 
an critical role in the development of cardiac dysfunction in DCM. 
Numerous researchers conducted other studies on the sarcoplasmic reticulum transport 
mechanism. Some of these are explained in the following text. 
In cardiac muscle, the SR has been shown to be the most active subcellular organelle 
implicated with the sequestration of activator calcium. SERCA 2a ATPase, together with 
sarcolemma NCX are responsible for lowering [Ca2+]i, leading to the relaxation of muscle. 
Experiments have shown that calcium binding and/or uptake by cardiac SR is altered in a 
variety of physiological and pathological states [99-101].   
Studies involving molecular cloning have identified a family of SERCA pumps encoded by the 
three homologous genes, SERCA1, SERCA2 and SERCA3 Of the 3 genes. The gene of interest 
here is the SERCA2, which is alternately spliced and encodes SERCA2a and SERCA2b isoforms 
[102]. SERCA2b isoform is expressed ubiquitously and is associated with inositol 
triphosphate (IP3) gated Ca2+ stores, whereas SERCA2a is the primary isoform expressed in 
the heart [103]. SERCA-2a ATPase is the major protein pump involved in the process of 
calcium reuptake into the sarcoplasmic reticulum [103]. Previous studies employing rats, 
mouse and rabbits have demonstrated that the expression of SERCA pump gradually 
increases during development [104-105]. Several other studies have shown that DCM is 
associated with decreased contractility and impaired relaxation [61]. As explained, the 
expression levels of SERCA pump protein appear to be a critical determinant of cardiac 
contractility. SERCA2a mRNA expression and protein level and activity have been 
demonstrated to be down-regulated in streptozotocin-induced (STZ) type 1 DM and the 
alteration of SERCA expression is accompanied by functional changes [105-106]. Studies 
from many laboratories have demonstrated that the expression level of SERCA is 
significantly decreased in pressure overload (Po) induced hypertrophy and HF [105-107]. 
Within these studies, the main finding has been decreased SR Ca2+ transport and function. In 
addition to animal studies on cardiac diseases, there is considerable evidence for alterations 
in SR Ca2+ transport and function. In end stage human HF, intracellular Ca2+ measurements 
using Fura-2 have shown markedly prolonged Ca2+ transients [Ca2+]i in both Ca2+ release and 
uptake phases in muscle samples from human hearts [102]. Further, other research by 
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Connelly and colleagues, revealed substantial reduction of SERCA-2a ATPase in diabetic Ren-
2 rats [109]. Upon examining the abundance of the inhibitory protein PLB, which is a 
regulator of SERCA 2a ATPase, a reduction of the active, phosphorylated from of PLN was 
observed in the diabetic state that is similar to that seen in the human hearts. Thus, it was 
predicted to reduce calcium transport and prevent actomyosin dissociation contributing to 
delayed relaxation and reduced contractility [110]. Lacombe et al. [111] reported that 
diabetes-induced diastolic dysfunction together with preserved overall systolic performance 
is coupled with abnormalities of intra-myocyte calcium regulation. Their findings included, 
prolonged Ca2+ transient decay, reduced intra-SR Ca2+ stores, reduced Ca2+ sparks, and 
decreased SERCA2a protein content, which were all consistent with decreased SR Ca2+ 
reuptake during the relaxation phase of cardiac myocytes. The decrease in SR Ca2+ load, 
combined with decreased ECC efficiency may contribute to the decrease in Ca2+ transient 
amplitude and Ca2+ spark frequency. One alternative mechanism for this approach could be 
defined as a compensatory mechanism via reduced SR Ca2+ leak which will enhance SR Ca2+ 
load [103,112] leading to the conclusion that impaired calcium reuptake during the diastolic 
phase, results from an impaired SERCA pump function. 
Dhalla et al. [58] reported that activation of sympathetic nervous system and RAAS as well 
platelet aggregation, endothelial dysfunction and generation of oxidative stress promote 
differential changes in SR activities and protein content during the development of diabetes. 
This result in alterations in SR function and SR remodeling occur in the diabetic heart. On 
the basis of these observations, it is suggested that oxidative stress and subcellular 
remodeling due to hormonal imbalance and metabolic defects play a critical role in the 
genesis of heart failure during the development of DCM. Remodeling of other subcellular 
organelles, including sarcolemma and myofibrils, has also been reported during the 
development of DCM [113-114]. 
Reduced calcium transients in diabetes mellitus  
During the last decade, accumulating evidence has been presented revealing that altered 
calcium homeostasis is of significant relevance for the pathophysiology of myocardial 
dysfunction and HF. Moreover, various mechanisms have been postulated as a result of 
many clinical and experimental studies. In addition, many outcomes have been identified 
from reduced Ca2+ transients and altered intracellular calcium cycling, reduced amplitude of 
Ca2+ transients with reduced systolic calcium concentrations and increased diastolic calcium 
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levels in isolated myocytes, together with decreased rates of SR calcium uptake in the failing 
human heart in type 1 DM [115-119]. Abnormal [Ca2+]i homeostasis has also been 
implicated in DCM and may precede clinical manifestation. Studies in cardiomyocytes have 
shown that diabetes results in impaired [Ca2+]i homeostasis due to altered SERCA and NCX 
activity [120]. Belke et al. [121] investigated contractile performance and Ca2+ transients in 
Langendorff-perfused hearts and isolated cardiac myocytes. They showed that in diabetic 
mouse hearts there was a decrease in rates of contraction, relaxation, and pressure 
development along with Ca2+ transients; significantly lower diastolic and systolic levels of 
calcium in myocytes from diabetic hearts. Furthermore, the decay rate of the Ca2+ transient 
was significantly reduced in diabetic myocytes, suggesting a diminished capacity for 
cytosolic calcium removal not associated with a change in NCX activity. Their study revealed 
that this decrease in contractile performance of the insulin-resistant (T2DM) diabetic model 
parallels the decrease in contractile performance observed in insulin-deficient (T1DM) 
diabetic models. However, recent study by Salem et al. [122] demonstrated no significant 
alterations in Ca2+ transients and L-type Ca2+ current in ventricular myocytes from 10-11 
months old Goto Kakizaki (GK) sedentary compared to control sedentary rats or by exercise 
training (2-3 months of treadmill exercise). A study by Zhang et al. [123] found no evidence 
to support the idea that altered Ca
2+ 
homeostasis underlies the contractile deficit of DCM. 
They postulated that the slower action potential and reduced SERCA2a expression could 
explain the slower Ca
2+ 
transient kinetics in diabetic rats, but not the contractile deficit. 
Instead, they suggest that the observed LV remodelling may play a crucial role that is 
explained elsewhere [124-125].  
 In conclusion, the observed changes in contractility and in [Ca2+]i handling are most likely 
attributable to functional disturbances of SERCA2a, NCX and RyR2 in this transitional phase 
of diabetes.  
 
Heart failure with normal ejection fraction  
Ejection fraction is the volume of blood (usually presented as a percentage) pumped out of 
the ventricles during each heartbeat or cardiac cycle. It is now extensively acknowledged 
that the clinical features of HF can occur in patients with normal left ventricular ejection 
fraction (LVEF) [126-128] a complex broadly referred to as HF with normal left ventricular 
ejection fraction (HFnEF). The finding of a reduced LVEF in patients with typical signs and 
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symptoms of HF provides objective proof that the patients suffer from cardiac abnormality 
and makes it obvious that the patient’s clinical syndrome is indeed HF.  
LV diastolic dysfunction is most commonly observed among patients with hypertension as 
well as the elderly [129]. While asymptomatic advanced LV diastolic dysfunction is also 
predictive of the future occurrence of HF [130], it is not clear why a number of patients with 
LV diastolic dysfunction have HFnEF while others remain asymptomatic. LV diastolic 
dysfunction has been suggested as the initial manifestation of diabetic heart disease in both 
T1DM and T2DM patients. In the Strong Heart Study [131], which investigated the effect of 
DM on LV filling pattern in normotensive and hypertensive individuals, T2DM was 
associated with an impaired relaxation pattern independently of age, blood pressure (BP), 
LV mass and LV systolic function.  
 
The occurrence of DM in HF is approximately 20-35% [132] and is to some extent higher in 
patients with HFnEF, at 30-40% [133]. HFnEF and T2DM commonly coexist. Both conditions 
are associated with hypertension, obesity and ageing [23], all of which promote the 
prevalence of HF. However, irrespective of underlying CVD, DM has a central role in HFnEF 
as demonstrated in the CHARM study [134] whereby the relative risk of cardiovascular 
death or HF hospitalization conferred by DM was significantly greater in patients with HFnEF 
compared with those with HFrEF [134]. The prevalence of HFnEF may be high even in 
asymptomatic and well-controlled diabetic subjects [135,136]. Regardless of the increased 
prevalence and poor outcome, pathophysiological features underlying HFnEF in DM remain 
uncertain [137]. A recent study by Ehl et al. [138] demonstrated a significantly lower LVEF in 
diabetic compared with non-diabetic patients (P<0.001) in a large patient population. Even 
though the difference was small, this finding may have important epidemiological impact, 
since LVEF is one of the most important predictors of survival. This hypothesis is supported 
by data from the Mayo clinic, which have confirmed a significantly worse survival of even 
asymptomatic diabetic patients with an LVEF of 50% [139].  
Various morphological changes occur in the diabetic heart leading to the abnormal 
physiological findings described above. These include increased extracellular collagen 
deposition, interstitial fibrosis, myocyte hypertrophy and intra-myocardial micro-
angiopathy. These changes are probably secondary to altered myocardial glucose and free 
fatty acid metabolism (FFA) in DM as outlined in Figure 3. 
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Figure 3: A schematic representation of the pathophysiological mechanisms underlying 
HFnEF in diabetes mellitus; drawn by hand.  
 
With respect to fibrosis and HFnEF, a population studied by van Heerebeek et al [140] 
showed different clinical characteristics to those observed in epidemiological studies. 
Consequently, as suggested by Connelly et al. [109], it should not be concluded that fibrosis 
does not contribute to HFnEF in DM. Several animal studies have demonstrated that fibrosis 
contributes to this syndrome [140] while human studies have shown that collagen volume 
fraction is increased approximately 2-fold in both DM and non-DM subjects with HFnEF 
[141]. Both fibrosis and cardiomyocyte are linked attributes to HFnEF in DM though the 
relative contribution of each remains under debate. Further research to unravel the 
pathophysiology of HFnEF in very well characterized patients and appropriate control 
subjects with a focus on the exercise response and the neuro-humoral axis is needed to 
establish therapeutic strategies [142].   
 
Role of myofilaments in cardiac dysfunction  
Myofilament properties have a major role in the governing cardiac relaxation. Though it is 
acknowledged that it is essential for the intracellular calcium concentration to decline in 
order to initiate and facilitate relaxation, the rate at which healthy myocardium relaxes is 
predominantly regulated by the properties of the myofilaments [143]. The peak of the 
[Ca2+]i amplitude is usually reached long before the peak of force development, and once 
force development initiates to decline, the Ca2+ concentration is near or below the 
concentration where the myofilament can begin activation.  
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DM is also known to be associated with a loss of cardiac myofibrils [144], which are the main 
contractile components for muscle contraction. Severe loss of myofibrils can lead to 
decreased contraction and cardiac output that are frequently reported in diabetic patients. 
Experiments conducted by Pierce and Dhalla [145], demonstrated that the basal ATPase 
activity of myofibrils from diabetic hearts was significantly lower than the controls over 8 
weeks. Their results also highlighted: (i) the basal and Ca2+ stimulated ATPase activities in 
diabetic rats demonstrated a greater sensitivity to KCl than control preparations, (ii) the 
myofibrillar basal ATPase, unlike Ca2+ stimulated ATPase, in diabetic animals exhibited a 
greater sensitivity to ethylene glycol and (iii) supports the view regarding the presence of 
some subtle structural and conformational changes in diabetic myofibrils. In subsequent 
work [146], diabetes was introduced in rats where they were maintained in a diabetic state 
for 6 weeks and then given 2 weeks of insulin treatment in vivo. The results obtained 
emphasized: (i) Mg2+-ATPase and Ca2+-stimulated ATPase activities were depressed in 
diabetic rat hearts in comparison to control, (ii) the depression in myofibrillar ATPases was 
of gradual onset as no changes were detected 2 weeks after inducing diabetes, (iii) Mg2+-
ATPase activity of myofibrillar preparations from control and diabetic hearts responded 
differently to N-ethylmaleimide modification, and interestingly and (iv) myofibrillar 
sulfhydryl reactivity to 5,5'-dithiobis (2-nitrobenzoic acid) was significantly depressed in 
diabetic preparations in comparison to control and insulin-treated diabetic animals. 
While many studies focused on animal studies, Jweied and colleagues [147] conducted a 
study to determine whether human diabetes mellitus is associated with depressed cardiac 
myofilament function. Assessment of Myofilament function was achieved by determination 
of the developed force-Ca2+concentration relation in skinned cardiac cells from flash frozen 
human biopsies. Separate control experiments revealed that flash freezing of biopsy 
specimens did not affect myofilament function. In this study, all patients in the DM group 
were classified as T2DM patients, and most showed signs of diastolic dysfunction. Data from 
the results revealed that DM was associated with depressed myofilament function, that is, 
decreased Ca2+ sensitivity (29%, P < 0.05 vs. control) and a trend toward reduction of 
maximum Ca2+-saturated force (29%, P = 0.08 vs. control). Results from this study 
highlighted that human diabetes mellitus is associated with decreased cardiac myofilament 
function and further, depressed cardiac myofilament Ca2+ responsiveness may underlie the 
decreased ventricular function characteristic of human diabetic cardiomyopathy. 
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Prevention, treatment and potential targets for DCM 
In order for proper and improved management options to be effective, it is essential to have 
better understanding of pathophysiology and pathogenesis in patients with DCM. These 
options include; lifestyle modification, glycaemic control, management of coexistent 
hypertension and heart failure. Some of aforementioned management options, in addition 
to emerging treatment modalities are discussed in the following section. 
Lifestyle modification  
Exercise training is necessary to maintain a healthy body and it is recognized that regular 
exercise with better diabetic control would have beneficial effects on the disease outcome.  
In a recent study [148] physical activity was associated with a significant reduction in 
cardiovascular disease and all-cause mortality in patients with DM in many clinical studies. 
Exercise training was beneficial for reducing the incidence of DCM in both human patients 
and animal models [149,150]. Weight loss, control of fat and regular physical activity can 
positively adjust metabolic abnormalities and thus improve systemic insulin resistance. 
Insulin resistance can be achieved by increasing post-receptor-signaling and increasing 
insulin-mediated glucose transport, which seems to be associated with signal transduction 
at the level of phosphatidylinositol 3-kinase and insulin receptor substrate [151,152]. In 
addition to exercise, maintaining healthy eating patterns that are suitable for diabetic 
patients can also be expected to show similar beneficial effects.  
Glycaemic control  
Clinical trials have demonstrated that poor glycaemic control has been associated with an 
increased risk of cardiovascular mortality – with an increase of 11% for every 1% rise in 
glycated haemoglobin (HbA1c) level [153]. It is expected that the effects of tight glycaemic 
control would be beneficial to patients because microvascular disease plays an important 
pathogenic role in the development of DCM. In one case-controlled study using cardiac MRI 
in patients with T1DM it was demonstrated that rigorous glycemic control was associated 
with better DCM outcome parameters [154] while in animal studies, improved glycaemic 
control delayed DCM in animal models [155]. However, other studies (UK Prospective 
Diabetes Study) failed to show a significant benefit of intensive blood glucose control using 
either sulphonylureas or insulin on the risk of developing macrovascular disease in patients 
with Type II diabetes [156]. 
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Anti-diabetic medication 
There are various classes of anti-diabetic drugs, and their selection depends on the nature 
of the diabetes, age, as well as other factors. Some of the more popular and effective drugs 
will be discussed in this section. These include: metformin, thiazolidinediones, empagliflozin, 
GLP-1 and DPP-4. 
Metformin, believed to be the most widely used medication for diabetes that is taken by 
mouth, upregulates cardiac autophagy, which is linked to DCM prevention and is primarily 
used to treat T2DM. Metformin facilitates glucose uptake and GLUT4 translocation in 
insulin-resistant cardiomyocytes and the myocardium by activating 5´-adenosine 
monophosphate-activated protein kinase [157]. This drug was reported to reduce mortality 
and improve the clinical outcome in overweight patients with HF and DM, however, 
metformin increase the production of lactate in the large intestine, which could potentially 
contribute to lactic acidosis [158].  
Thiazolidinediones (TZDs) are a class of insulin sensitizers compounds for treating patients 
with T2DM.  They act by increasing insulin sensitivity in skeletal muscle and adipose tissue 
through binding and activation of PPAR-γ, a nuclear receptor that has a regulatory role in 
differentiation of cells [159]. 
Apart from insulin-sensitizing fat and skeletal muscle, TZDs increase the expression and 
function of glucose transporters in the heart, leading to improved glucose metabolism, and 
reduce non-esterified fatty acids (NEFA) utilization by the myocardium [160]. However, 
thiazolidinedione therapy can cause chronic symptoms that resemble heart failure. 
Therefore, the drug is generally not recommended in patients with heart failure.  
Empagliflozin is a new anti-diabetic drug of the gliflozin class that was approved for 
treatment of T2DM in 2014.  It is an inhibitor of sodium-glucose co-transporter 2 (SGLT-2), 
which reduces HbA1c levels in patients with T2DM by controlling visceral adiposity, blood 
pressure, arterial stiffness, albuminuria, weight, oxidative stress, hyperinsulinemia, and 
circulating uric acid levels [161]. 
Glucagon-like peptide-1 (GLP-1) is a known incretin that has the ability to decrease blood 
sugar levels in a glucose-dependent manner by enhancing the secretion of insulin. Synthetic 
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GLP-1, which has a longer half-life than natural GLP-1, has shown to attenuate myocardial 
apoptosis and enhance vasodilation [162]. This new group of drugs has shown promise in 
the management strategy in obese T2DM patients with DCM and further, GLP-1-based 
treatment has been associated with weight loss and lower hypoglycemia risks. 
Dipeptidyl peptidase 4 (DPP-4) is an enzyme that metabolizes endogenous GLP-1. DPP-4 
inhibitors can prevent cardiac diastolic dysfunction and cardiac hypertrophy by inhibiting 
fibrosis and oxidative stress in mouse models of insulin resistance and obesity [163]. 
 
Statins  
 
Statins (hydroxymethylglutaryl CoA reductase inhibitors) is a class of drug that lowers the 
level of cholesterol in the blood by reducing the production of cholesterol by the liver. 
Statins works by inhibiting HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A 
reductase), an enzyme found in liver tissue that plays a key role in the production of 
cholesterol in the body. 
In multiple clinical trials [164] it was found that the use of statins reduces cardiovascular 
mortality and events in patients with diabetes and vascular risk factors, and it is beneficial 
even for primary prevention in patients without established cardiovascular disease [165].  
It has been reported that atorvastatin, a lipid-lowering agent, reduces myocardial fibrosis, 
intramyocardial inflammation, and improves LV function in rat models of experimental 
DCM, independently of its LDL-C-lowering capacity [166]. Likewise, fluvastatin is useful for 
attenuating cardiac dysfunction and myocardial interstitial fibrosis in rat models of the 
disease [167].  
 
Vasoactive medications - blockers and inhibitors 
 
Many vasoactive medications have been tried in both animal and human patients models 
with DCM, with variable results. 
-blocker is a class of medications that are particularly used to manage abnormal heart 
rhythms, and to protect the heart from myocardial infraction after a first heart attack.  
Initially, there was a reluctance to use β-blockers in patients with diabetes for fear of 
adverse effects on insulin resistance and an unawareness of hypoglycaemia. However, with 
the recent advances in the understanding of HF and the realization of the importance of the 
SNS in the release of vasoactive substances, they have become an essential treatment for 
HF [168].  
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Earlier studies of β-blockers in the early 90’s involved recruited patients with advanced HF 
and, although LV function improved, mortality did not [169,170]. However, subsequent 
studies enrolled patients with mild-to-moderate HF and showed significant reductions in 
mortality rate of 32% and 34 % respectively [171,172]. The third generation β-blocker 
carvedilol, which antagonizes both α and β receptors, has been proven to have a highly 
significant effect on mortality (67% reduction) in patients with severe HF [173]. Other β-
blocker such as bisoprolol and metoprolol have been shown in large-scale randomized 
controlled trials to reduce heart failure mortality [174] and more recently, Sharma et al. 
demonstrate that β-Adrenoreceptor blockers were effective in experimental models of DCM 
[175]. 
The importance of (RAAS) antagonism in the prevention of diabetic CVD has demonstrated 
the key role that the RAAS plays in diabetic CVD onset and development. Angiotensin 
converting enzyme (ACEi) inhibitors and angiotensin II receptor blockers (ARB) represent the 
first line therapy for primary and secondary CVD prevention in patients with diabetes [176]. 
 (ACEi), renin inhibitor (aliskiren) and (ARB) were all shown to be protective against DCM in 
rat models [177]. Other studies have demonstrated that ACEis and ARBs were also beneficial 
in both human and animal models of DCM [178,179].  
Recently, Poly (ADP-ribose) polymerase (PARP) inhibitors have stimulated much excitement. 
PARP-1 is a member of the PARP enzyme family and is one of the most abundant nuclear 
proteins which functions as a DNA-nick-sensor enzyme [180]. Research conducted by Du et 
al. [181] revealed that hyperglycemia-induced overproduction of superoxide by the 
mitochondrial electron transport chain activates the three major pathways of hyperglycemic 
damage found in aortic endothelial cells by inhibiting GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) activity. Thus, inhibition of PARP blocks hyperglycemia-induced activation 
of multiple pathways of vascular damage and provides a unique approach as it blocks 
activation of all the major pathways thought to mediate tissue damage in diabetes. 
 
Metabolic modulators 
 
Metabolic modulators are a newer class of drugs that benefit patients by modulating cardiac 
metabolism without altering hemodynamics. They have the potential to relieve symptoms in 
patients with refractory heart failure who are already on optimal medical therapy. These 
drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby 
enhancing efficient use of oxygen. Three metabolic modulators drugs that could potentially 
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be used for HF therapy and CDM are: trimetazidine, resveratrol and ranolazine. 
 
Trimetazidine, a competitive inhibitor of the terminal enzyme in β-oxidation has promising 
beneficial effects on heart failure in diabetic patients with both idiopathic and ischemic 
dilated cardiomyopathy [182]. Studies of animal models revealed that trimetazidine reduce 
free radical injury, improve endothelial function, inhibit apoptosis and attenuate lipotoxicity 
[183]. However, human trials are needed to investigate the beneficial effects of this drug on 
the treatment and prevention of DCM. Studies on resveratrol revealed that it reduces 
glucose levels; improve triglyceride level, heart rate, and glycemia [184] while ranolazine, a 
potent late Na+ current inhibitor, normalize altered cardiomyocyte intracellular calcium 
concentration due to the close relationship between Ca2+ and Na+ handling by the Na+/Ca2+ 
exchanger [186]. 
 
New therapeutic directions  
Within the past five years, research into new therapeutic direction focused on the areas of 
cell/genetic therapy and targeting mitochondrial oxidative stress. A few of these new 
emerging treatment modalities will be discussed in this section. An excellent review on this 
topic was done by Huynk et al. [186] in which they discussed both conventional and novel 
therapeutic approaches for the treatment of left ventricular dysfunction in diabetic patients. 
 
mi-RNA. 
The dysregulation of micro-ribonucleic acid (mi-RNA) function serve as an important 
pathogenic mechanism of diabetes and its complications. mi-RNAs have been reported to be 
potential biomarker for early detection of DCM and they have become the subject of an 
active area of research to establish their potential contribution to heart disease in patients 
with T2DM. The noncoding RNA, miR-223 was found to be associated with regulation of 
GLUT4 expression in adult cardiomyocytes [187] while data from experimental studies 
underscore the contribution of miR-21 in stimulating MAP kinase signaling in mouse 
fibroblasts, consequently promoting fibrosis and contractility alterations as features of DCM 
in diabetic animal models [188,189]. Other research have implicated miRNA to be involved 
in regulating extracellular signal regulated kinases (ERK) in diabetic conditions and 
therefore, modulating ERK1/2 derived-pathway which opposes oxidative stress-induced 
insulin resistance in cardiomyocytes [190]. 
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Coenzyme Q10. 
Recent research by Mortensen et al. [191], on the effect of coenzyme Q10 on morbidity and 
mortality in chronic heart failure patients using randomized controlled trial, showed that 
long-term coenzyme Q10 treatment in patients with chronic heart failure is safe, improves 
symptoms, and reduces all-cause mortality by 42% and cardiovascular death by 43%. Other 
reports have also established that coenzyme Q10 improves cardiac function in patients with 
DM and concurrent heart failure [192,193]. 
 
Pim-1.  
Pim-1 (serine/threonine-protein kinase pim-1) gene therapy was shown to improve LV 
diastolic function, prevent cardiac apoptosis, fibrosis, and development of HF [194]. While in 
other studies [195], it was demonstrated that Pim-1 downregulation contributes in the 
pathogenesis of diabetic cardiomyopathy. Thus, establishing that intravenous gene therapy 
with pim-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy 
through promotion of pro-survival signaling and represents a novel and effective approach 
to treat the disease. 
 
Phosphoinositide 3-kinase. 
In a very recent research, Prakoso and colleagues [196] investigated the therapeutic 
potential of a delayed intervention with cardiac-targeted phosphoinositide 3-kinase (PI3K) 
gene therapy, administered to mice with established diabetes-induced LV diastolic 
dysfunction. After study endpoint, it was discovered that diabetes-induced LV dysfunction 
was significantly attenuated by a single administration of recombinant adeno-associated-
virus 6-constitutively active PI3K (p110α) (rAAV6-caPI3K), administered 8 weeks after the 
induction of diabetes. Their results clearly demonstrate that cardiac-targeted PI3K (p110α) 
gene therapy limits diabetes-induced up-regulation of NADPH oxidase and cardiac 
remodelling suggests new insights into promising approaches for the treatment of diabetic 
cardiomyopathy. 
 
Szeto-Schiller peptide.  
The SS (Szeto-Schiller) peptide antioxidants represent a novel approach with targeted 
delivery of antioxidants to the inner mitochondrial membrane. The structural motif of these 
SS peptides centers on alternating aromatic residues and basic amino acids (aromatic-
cationic peptides). These SS peptides can scavenge hydrogen peroxide and peroxynitrite and 
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inhibit lipid peroxidation. By reducing mitochondrial ROS, these peptides inhibit 
mitochondrial permeability transition and cytochrome c release, thus preventing oxidant-
induced cell death [197]. 
The Szeto-Schiller peptide d-Arg-2′, 6′-dimethyltyrosine-Lys-Phe-NH2 (SS31) is a positively 
charged free-radical scavenger that can accumulate to high levels in the mitochondria and 
prevent diastolic dysfunction, fibrosis, and cardiac hypertrophy [192].  
This technique represents a promising approach for preventing DCM by targeting excess 
myocardial ROS with novel antibiotics. 
 
Conclusion 
The prevalent rise in DM worldwide has made DCM an increasing health concern. As the 
incidence and prevalence of DM continue to rise, HG-induced structural and ultrastructural 
changes may cause a reduction in heart perfusion and eventually HF. A variety of treatment 
options have shown to be effective in treating DCM and novel therapeutic strategies, such 
as gene therapy targeting the phosphoinositide 3-kinase PI3K (p110α), signaling pathway, 
and miRNA dysregulation have shown good promise. In addition to these, targeting redox 
stress and mimetic peptides targeting calcium channels may represent a future strategy for 
combating the ever-increasing incidence of heart failure in the diabetic population. 
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